

**WINSTON PHARMACEUTICALS, INC. (FORMERLY GETTING READY CORPORATION)
COMMENCES TRADING UNDER NEW NAME AND STOCK SYMBOL**

Vernon Hills, IL – January 15, 2009 – Today, Winston Pharmaceuticals, Inc. (formerly known as Getting Ready Corporation) (the “Company”), the parent company of Winston Laboratories, Inc., announced that effective January 16, 2009 the Company’s common stock would begin trading on the OTC Bulletin Board as Winston Pharmaceuticals, Inc. under the new stock symbol “WPHM,” and that quotations of the Company’s common stock will no longer be available under the old “GTRY” stock symbol. The Company also announced that beginning tomorrow, all quotations of the Company’s common stock on the OTC Bulletin Board will reflect the Company’s eight-to-one reverse stock split.

About Winston Pharmaceuticals

Winston Pharmaceuticals is a development stage pharmaceutical company focused on pain control. Winston is developing products for large pain control markets, as well as for niche markets, where there are still significant unmet needs for pain management options with improved efficacy, safety, and tolerability profiles. Winston’s product candidates span a range of pain indications, including osteoarthritis, neuropathic pain, cancer pain, post-operative pain, episodic cluster headache and chronic daily headache.

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

CONTACT: Winston Pharmaceuticals, Inc.

David Starr, Chief Financial Officer
(847) 362-8200